Notice: This company has been marked as potentially delisted and may not be actively trading. Medicines (MDCO) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Lobbying Update: $2,710,000 of PFIZER INC. lobbying was just disclosedJanuary 17, 2025 | quiverquant.comBlueprint Medicines shares surge on growth strategy and upbeat trial dataJanuary 13, 2025 | investing.comBlueprint Medicines Highlights 2024 Achievements and Future GrowthJanuary 13, 2025 | tipranks.comBlueprint Medicines Surges Over 10% as 2025 Growth Strategy Ignites InvestorJanuary 13, 2025 | gurufocus.comNuformix PLC Pursues Orphan Drug Designation for NXP002 and Explores Partnership OpportunitiesJanuary 13, 2025 | tipranks.comPraxis Precision Medicines Inc (PRAX) Announces Significant Progress in CNS Disorder TherapiesJanuary 12, 2025 | gurufocus.comPraxis Precision Medicines Highlights 2025 Corporate Strategy and Business PrioritiesJanuary 12, 2025 | investing.comPraxis Precision Medicines Highlights 2025 Corporate Strategy and Business PrioritiesJanuary 12, 2025 | gurufocus.comBlueprint Medicines Corp (BPMC) Unveils 2025 Growth Strategy and Promising Clinical DevelopmentsJanuary 12, 2025 | gurufocus.comBlueprint Medicines Corp (BPMC) Unveils 2025 Growth Strategy and Promising Clinical DevelopmentsJanuary 12, 2025 | gurufocus.comBiotech startup raises $120 million in bid to reset the immune systemJanuary 10, 2025 | bizjournals.comEverest Medicines Updates Hong Kong Business AddressJanuary 10, 2025 | tipranks.comEverest Medicines Reports Unusual Trading Activity Amid Shareholder TransactionJanuary 8, 2025 | tipranks.comRevolution Medicines Inc (RVMD) to Present at J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | gurufocus.comPraxis Precision Medicines to Present at J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | gurufocus.comPraxis Precision Medicines Inc (PRAX) to Present at J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | gurufocus.comTYK Medicines Approves Key Resolutions at EGMJanuary 3, 2025 | tipranks.comPraxis Precision Medicines: Multiple Potential DriversDecember 26, 2024 | seekingalpha.comCytokinetics' Aficamten Marketing Authorization Application Validated by European Medicines Agency for Obstructive Hypertrophic Cardiomyopathy TreatmentDecember 23, 2024 | quiverquant.comInsider Sell: Christina Rossi Sells Shares of Blueprint Medicines Corp (BPMC)December 21, 2024 | gurufocus.com3D Medicines Inc. Shifts Focus to NSCLC TrialDecember 19, 2024 | tipranks.comTYK Medicines to Discuss Strategic Expansions in 2025December 19, 2024 | tipranks.comTYK Medicines Secures Approval for H Share CirculationDecember 19, 2024 | tipranks.comSangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological DiseasesDecember 19, 2024 | investing.comAstellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological DiseasesDecember 19, 2024 | investing.comNovo Nordisk's Ozempic Under Scrutiny For Potential Increased Risk Of Rare-Eye DiseaseDecember 18, 2024 | benzinga.comNovo Nordisk’s (NYSE:NVO) Ozempic to Be Investigated for Eye Disorder LinkDecember 17, 2024 | tipranks.comCSL receives positive CHMP opinion for garadacimab in HAEDecember 13, 2024 | tipranks.comTYK Medicines Revises Articles of Association Amid Legal ChangesDecember 13, 2024 | tipranks.comBiotech Nintx Raises US$ 10 Million to Advance a New Generation of Medicines Based on Brazilian BiodiversityDecember 13, 2024 | financialpost.comBiotech Nintx Raises US$ 10 Million to Advance a New Generation of Medicines Based on Brazilian BiodiversityDecember 13, 2024 | financialpost.comGilead announces positive CHMP opinion for seladelparDecember 13, 2024 | tipranks.comTheratechnologies Secures Canadian Rights for Ionis RNA MedicinesDecember 12, 2024 | tipranks.comBlueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic ...December 7, 2024 | gurufocus.comBlueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual MeetingDecember 7, 2024 | investing.comRevolution Medicines price target lowered to $62 from $68 at NeedhamDecember 6, 2024 | tipranks.comRevolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional SharesDecember 5, 2024 | investing.comRevolution Medicines: Risky Buy On Recent Share Price DipDecember 4, 2024 | seekingalpha.comRevolution Medicines price target raised to $72 from $64 at H.C. WainwrightDecember 4, 2024 | tipranks.comRevolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded WarrantsDecember 3, 2024 | investing.comRevolution Medicines price target raised to $87 from $82 at GuggenheimDecember 3, 2024 | tipranks.comRevolution Medicines price target raised to $71 from $63 at JPMorganDecember 2, 2024 | tipranks.comRevolution Medicines price target raised to $80 from $70 at StifelDecember 2, 2024 | tipranks.comRevolution Medicines reports progress in cancer drug trialsDecember 2, 2024 | investing.comEverest Medicines Announces Acceptance of VELSIPITY New Drug Application in Hong KongDecember 1, 2024 | gurufocus.comPraxis Precision to present preclinical, clinical data from epilepsy programsNovember 26, 2024 | tipranks.comAnavex announces submission of blarcamesine MAA to EMANovember 26, 2024 | tipranks.comBlueprint Medicines director Coats sells $1.87 million in stockNovember 22, 2024 | investing.comNurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 ...November 20, 2024 | gurufocus.comRA Capital Management Reduces Stake in Praxis Precision Medicines IncNovember 15, 2024 | gurufocus.com Get Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for MDCO and its competitors with MarketBeat's FREE daily newsletter. Email Address MDCO Media Mentions By Week MDCO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MDCO News Sentiment▼0.000.63▲Average Medical News Sentiment MDCO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MDCO Articles This Week▼11▲MDCO Articles Average Week Get Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for MDCO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RPRX News Today JAZZ News Today CORT News Today PRGO News Today SUPN News Today PCRX News Today OMER News Today NKTR News Today ASMB News Today CPIX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MDCO) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThe Crypto Secret Wall Street Doesn’t Want You to KnowPotential $20-trillion opportunity? Put $500 into THIS AI Coin for 2025… Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding The Medicines Company Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
